Top 10 Cancer Drugs Market to Reach $129,948 Million, at CAGR of 9.8% by 2025 with Companies are AbbVie Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation

The top 10 cancer drugs market accounted for $63,619 million in 2018, and is expected to reach $129,948 million by 2026, registering a CAGR of 9.8% from 2019 to 2026.

Cancer caused when the cells present in the body grow at an uncontrolled rate leading to the formation of a tumor. Cancer has different stages based on its progression. Metastasis is the final stage of the disease, which is marked by the invasion of tumor into others parts of body. The management of cancer in patients requires the use of different forms of drugs such as hormonal therapy, immunotherapy, targeted therapy, and others.

Download Free Report Sample @ https://www.alliedmarketresearch.com/request-sample/6225

Drugs such as Revlimid, Opdivo, Keytruda, Herceptin, Avastin, Rituxan, Imbruvica, Neulasta/Peglasta, Ibrance, and Zytiga are the top selling drugs in 2018. The key drivers of the global cancer drugs market are increase in incidence of cancer, rise in adoption of advance therapies such as biological & targeted drug therapies, surge in geriatric population, and rise in collaborations & partnerships to facilitate drug development. In addition, availability of the drugs and increase in healthcare expenditure have significantly contributed toward the growth of this market. Increase in number of pipeline drugs along with high potential of emerging economies are further expected to provide lucrative opportunities for market expansion. However, high cost involved in new drug development and adverse effects related to cancer drugs are expected to impede the market growth.

The global top 10 cancer drugs sales is segmented on the basis of region. Regionally, the market is studied across Europe (Russia, Netherlands, Switzerland, Sweden, Belgium, Austria, Norway, Denmark, Poland, Finland, Portugal, Greece, Ireland, Czech Republic, Hungary, Romania, Ukraine), Asia-Pacific (Taiwan, Indonesia, New Zealand, Singapore, Malaysia, Vietnam, Myanmar, Sri Lanka, Macau, Nepal), and LAMEA (Turkey, Venezuela, Colombia, Argentina, Iran, Israel, Chile, Algeria, United Arab Emirates, Puerto Rico, Morocco, Costa Rica, Lebanon).

Inquiry Before Buying @ https://www.alliedmarketresearch.com/purchase-enquiry/6225

In the current scope of the study, Europe was the leading revenue contributor to the market in 2018, owing to high adoption rate of cancer drugs. However, Asia-Pacific is expected to grow at the highest CAGR from 2019 to 2026, owing to increase in adoption of advanced therapies, surge in research, development, & innovation activities; and rise in awareness related to different cancers.

The Major Key Players Are:

o AbbVie Inc.
o Astellas Pharma Inc.
o AstraZeneca PLC
o Bristol-Myers Squibb Company
o Celgene Corporation
o F. Hoffmann-La Roche Ltd.
o Johnson & Johnson (Janssen Global Services, LLC,)
o Merck & Co., Inc.
o Novartis AG
o Pfizer Inc.

Obtain Report Details @ https://www.alliedmarketresearch.com/top-10-cancer-drugs-market

Key Findings of the Top 10 Cancer Drugs Market :

o Revlimid occupied 15.22% share of the global top 10 cancer drugs sales in 2018.
o Keytruda is anticipated to grow at the highest rate during the analysis period.
o The Europe cancer drugs accounted for 21.21% share of the global top 50 cancer drugs sales in 2018.
o The top 10 cancer drugs accounted for 52.96% share of the global top 50 cancer drugs sales in 2018.
o Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA

Similar Reports:

Cancer Vaccines Market: https://www.globenewswire.com/news-release/2019/06/12/1867652/0/en/Global-Cancer-Vaccines-Market-to-Reach-12-81-Billion-by-2023-AMR.html

Cancer Immunotherapy Market: https://www.medgadget.com/2019/03/latest-study-says-cancer-immunotherapy-market-to-grow-faster-due-to-extensive-use-of-cancer-immunotherapy-in-the-hospitals-2014-2022.html

Cancer Therapeutics Market: https://www.medgadget.com/2019/10/global-cancer-therapeutics-market-is-anticipated-to-reach-180-19-bn-by-2026.html

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client's insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

This release was published on openPR.